Vitamin E in the prevention of vancomycin-induced nephrotoxicity

Rasool Soltani , Farzin Khorvash, Mohsen Meidani, Shirinsadat Badri , Sajedeh Alae, Shahram Taheri

Abstract


Background and purpose: The use of vancomycin, as a key therapeutic choice for treatment of hazardous infections, may be associated with nephrotoxicity. The proposed mechanism is the indirect production of reactive oxygen species and oxidative stress. The purpose of this study was to investigate the effect of vitamin E as an antioxidant agent in the prevention of vancomycin-induced nephrotoxicity.

Experimental approach: In a matched-groups interventional study, patients who received vancomycin for any indication were assigned to vitamin E (n = 30) and control (n = 60) groups. The patients in experimental group received 400 units of oral vitamin E per day for 10 days started concurrently with vancomycin, while the patients in control group received vancomycin alone. Serum level of creatinine, blood urea nitrogen (BUN), creatinine clearance (CrCl), and 24-h urine output were determined and recorded before the start of interventions, every other day during therapy, and 12 h after the last dose of vancomycin in 10th day of therapy for all patients. Also, the rate of acute kidney injury (AKI) in the two groups was recorded. Finally, the mean values of the measured parameters were compared between the groups.

Findings / Results: Treatment with vitamin E for 10 days resulted in a significant reduction of BUN (from 17.5 ± 7.8 mg/dL at baseline to 11.4 ± 4.8 mg/dL at the end; P < 0.001) along with slightly non-significant increase of CrCl (from 84.7 ± 18.9 mL/min at baseline to 91.3 ± 19.5 mL/min at the end; P = 0.301) in comparison to the control group. However, CrCl decreased significantly in the control group. Vitamin E had no significant effect on 24-h urine output. Regarding vancomycin-induced AKI, 12 cases were observed in the control group, while no case was reported in experimental group (P = 0.041).

Conclusion and implications: This study showed the beneficial effect of add-on therapy of vitamin E besides vancomycin in reducing AKI, which could be considered as a new potential prophylactic therapy for vancomycin-induced nephrotoxicity.

 


Keywords


Acute kidney injury; Nephrotoxicity; Vancomycin; Vitamin E.

Full Text:

PDF

References


Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98.

DOI: 10.2146/ajhp080434.

Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123(2):182.e1-7,1-11.

DOI: 10.1016/ j.amjmed.2009.05.031.

Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. a literature review. Eur J Clin Pharmacol. 2012;68(9):1243-1255.

DOI: 10.1007/ s00228-012-1259-9.

Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26(6):876-879. DOI: 10.1248/bpb.26.876.

Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459-469. DOI: 10.1002/cpt.726.

Khoei A, Soltani R, Emami J, Badri S, Taheri S. Therapeutic drug monitoring of vancomycin by AUCτ-MIC ratio in patients with chronic kidney disease. Res Pharm Sci. 2019;14(1):84-92.

DOI: 10.4103/1735-5362.251856.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325-327.

DOI: 10.1086/600877.

Elyasi S, Khalili H, Hatamkhani S, Dashti-Khavidaki S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol. 2013;69(4):747-754.

DOI: 10.1007/s00228-012-1406-3.

Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats: protective role of melatonin. J Pineal Res. 2003;35(2):85-90.

DOI: 10.1034/j.1600-079x.2003.00059.x.

Parlakpinar H, Tasdemir S, Polat A, Bay-Karabulut A, Vardi N, Ucar M, et al. Protective role of caffeic acid phenethyl ester (cape) on gentamicin-induced acute renal toxicity in rats. Toxicology. 2005;207(2):169-177.

DOI: 10.1016/ j.tox.2004.08.024.

Ozen S, Akyol O, Iraz M, Söğüt S, Ozuğurlu F, Ozyurt H, et al. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol. 2004;24(1):27-35. DOI: 10.1002/jat.941.

Ocak S, Gorur S, Hakverdi S, Celik S, Erdogan S. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007;100(5):328-333.

DOI: 10.1111/j.1742-7843.2007.00051.x.

Ahmida MH. Protective role of curcumin in nephrotoxic oxidative damage induced by vancomycin in rats. Exp Toxicol Pathol. 2012;64(3):149-153.

DOI: 10.1016/ j.etp.2010.07.010.

Panonnummal R, Varkey J, Dinoop DR. Protective effect of atorvastatin against vancomycin induced nephrotoxicity in albino rats. Pharmacie Globale (IJCP) 2011;8(10):1-6.

Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol. 2001;54(3):176-186.

DOI: 10.1136/jcp.54.3.176.

Aslanturk A, Uzunhisarcikli M, Kalender S, Demir F. Sodium selenite and vitamin E in preventing mercuric chloride induced renal toxicity in rats. Food Chem Toxicol. 2014;70:185-190.

DOI: 10.1016/j.fct.2014.05.010.

Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther. 2007;30(5):477-481.

DOI: 10.1111/j.1365-2885.2007.00901.x.

Ajith TA, Usha S, Nivitha V. Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta. 2007;375(1-2):82-86.

DOI: 10.1016/j.cca.2006.06.011.

World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-374.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

DOI: 10.1007/s00134-012-2769-8.

Hemati S, Arbab Jolfaie N, Gookizadeh A, Rafienia M, Ghavamnasiri MR. The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: a randomized, placebo-controlled study. J Res Med Sci. 2012;1:S49-S58.

Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622-627. DOI: 10.1053/j.ajkd.2010.02.337.

KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.

Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol. 2005;97(5):325-332.

DOI: 10.1111/j.1742-7843.2005.pto_153.x.

Aslanturk A, Uzunhisarcikli M, Kalender S, Demir F. Sodium selenite and vitamin E in preventing mercuric chloride induced renal toxicity in rats. Food Chem Toxicol. 2014;70:185-190.

DOI: 10.1016/j.fct.2014.05.010.

Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther. 2007;30(5):477-481.

DOI: 10.1111/j.1365-2885.2007.00901.x.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.